Serum antibodies to HPV16 early proteins warrant investigation as potential biomarkers for risk stratification and recurrence of hpv-associated oropharyngeal cancer

Carole Fakhry, Jesse R. Qualliotine, Zhe Zhang, Nishant Agrawal, Daria A. Gaykalova, Justin A. Bishop, Rathan M. Subramaniam, Wayne M. Koch, Christine H. Chung, David W. Eisele, Joseph Califano, Raphael P. Viscidi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Human papillomavirus (HPV) is responsible for increasing incidence of oropharyngeal cancer. At present, there are no biomarkers in the surveillance algorithm for HPV-positive oropharyngeal cancer (HPV-OPC). HPV16 E6 antibody precedes oropharyngeal cancer diagnosis. If HPV16 E6 indeed precedes primary diagnosis, it is similarly expected to precede disease recurrence and may have a potential role as a biomarker for surveillance of HPV-OPC. To determine whether HPV antibody titers have a potential role as early markers of disease recurrence or prognosis, a retrospective pilot study was designed to determine whether HPV16 early antibody titers E6, E7, E1, and E2 decrease after treatment of HPV16-positive OPC. Trends in pretreatment, early (6 months after treatment), and late posttreatment (>6 months after treatment) HPV16 antibody titers were examined. There were 43, 34, and 52 subjects with serum samples available for pretreatment, early, and late posttreatment intervals. Mean pretreatment antibody levels were higher than posttreatment antibody levels. Average antibody levels decreased significantly over time for E6 (Ptrend  0.001) and E7 (Ptrend <0.001). Six disease recurrences were observed during the follow-up period (median, 4.4 years). In univariate analysis, a log-unit increase in pretreatment E6 titer was significantly associated with increased risk of disease recurrence (HR, 5.42; 95% CI, 1.1â€"25.7; P  0.03). Therefore, levels of antibodies to HPV16 early oncoproteins decline after therapy. Higher E6 titers at diagnosis are associated with significant increases in the risk of recurrence. These data support the prospective evaluation of HPV16 antibodies as markers of surveillance and for risk stratification at diagnosis.

Original languageEnglish (US)
Pages (from-to)135-141
Number of pages7
JournalCancer Prevention Research
Volume9
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Oropharyngeal Neoplasms
Biomarkers
Recurrence
Antibodies
Serum
Proteins
Oncogene Proteins
Retrospective Studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum antibodies to HPV16 early proteins warrant investigation as potential biomarkers for risk stratification and recurrence of hpv-associated oropharyngeal cancer. / Fakhry, Carole; Qualliotine, Jesse R.; Zhang, Zhe; Agrawal, Nishant; Gaykalova, Daria A.; Bishop, Justin A.; Subramaniam, Rathan M.; Koch, Wayne M.; Chung, Christine H.; Eisele, David W.; Califano, Joseph; Viscidi, Raphael P.

In: Cancer Prevention Research, Vol. 9, No. 2, 01.02.2016, p. 135-141.

Research output: Contribution to journalArticle

Fakhry, Carole ; Qualliotine, Jesse R. ; Zhang, Zhe ; Agrawal, Nishant ; Gaykalova, Daria A. ; Bishop, Justin A. ; Subramaniam, Rathan M. ; Koch, Wayne M. ; Chung, Christine H. ; Eisele, David W. ; Califano, Joseph ; Viscidi, Raphael P. / Serum antibodies to HPV16 early proteins warrant investigation as potential biomarkers for risk stratification and recurrence of hpv-associated oropharyngeal cancer. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 2. pp. 135-141.
@article{b33977d618d4499bad683a43a501d01d,
title = "Serum antibodies to HPV16 early proteins warrant investigation as potential biomarkers for risk stratification and recurrence of hpv-associated oropharyngeal cancer",
abstract = "Human papillomavirus (HPV) is responsible for increasing incidence of oropharyngeal cancer. At present, there are no biomarkers in the surveillance algorithm for HPV-positive oropharyngeal cancer (HPV-OPC). HPV16 E6 antibody precedes oropharyngeal cancer diagnosis. If HPV16 E6 indeed precedes primary diagnosis, it is similarly expected to precede disease recurrence and may have a potential role as a biomarker for surveillance of HPV-OPC. To determine whether HPV antibody titers have a potential role as early markers of disease recurrence or prognosis, a retrospective pilot study was designed to determine whether HPV16 early antibody titers E6, E7, E1, and E2 decrease after treatment of HPV16-positive OPC. Trends in pretreatment, early (6 months after treatment), and late posttreatment (>6 months after treatment) HPV16 antibody titers were examined. There were 43, 34, and 52 subjects with serum samples available for pretreatment, early, and late posttreatment intervals. Mean pretreatment antibody levels were higher than posttreatment antibody levels. Average antibody levels decreased significantly over time for E6 (Ptrend {\^A} 0.001) and E7 (Ptrend <0.001). Six disease recurrences were observed during the follow-up period (median, 4.4 years). In univariate analysis, a log-unit increase in pretreatment E6 titer was significantly associated with increased risk of disease recurrence (HR, 5.42; 95{\%} CI, 1.1{\^a}€{"}25.7; P {\^A} 0.03). Therefore, levels of antibodies to HPV16 early oncoproteins decline after therapy. Higher E6 titers at diagnosis are associated with significant increases in the risk of recurrence. These data support the prospective evaluation of HPV16 antibodies as markers of surveillance and for risk stratification at diagnosis.",
author = "Carole Fakhry and Qualliotine, {Jesse R.} and Zhe Zhang and Nishant Agrawal and Gaykalova, {Daria A.} and Bishop, {Justin A.} and Subramaniam, {Rathan M.} and Koch, {Wayne M.} and Chung, {Christine H.} and Eisele, {David W.} and Joseph Califano and Viscidi, {Raphael P.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0299",
language = "English (US)",
volume = "9",
pages = "135--141",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Serum antibodies to HPV16 early proteins warrant investigation as potential biomarkers for risk stratification and recurrence of hpv-associated oropharyngeal cancer

AU - Fakhry, Carole

AU - Qualliotine, Jesse R.

AU - Zhang, Zhe

AU - Agrawal, Nishant

AU - Gaykalova, Daria A.

AU - Bishop, Justin A.

AU - Subramaniam, Rathan M.

AU - Koch, Wayne M.

AU - Chung, Christine H.

AU - Eisele, David W.

AU - Califano, Joseph

AU - Viscidi, Raphael P.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Human papillomavirus (HPV) is responsible for increasing incidence of oropharyngeal cancer. At present, there are no biomarkers in the surveillance algorithm for HPV-positive oropharyngeal cancer (HPV-OPC). HPV16 E6 antibody precedes oropharyngeal cancer diagnosis. If HPV16 E6 indeed precedes primary diagnosis, it is similarly expected to precede disease recurrence and may have a potential role as a biomarker for surveillance of HPV-OPC. To determine whether HPV antibody titers have a potential role as early markers of disease recurrence or prognosis, a retrospective pilot study was designed to determine whether HPV16 early antibody titers E6, E7, E1, and E2 decrease after treatment of HPV16-positive OPC. Trends in pretreatment, early (6 months after treatment), and late posttreatment (>6 months after treatment) HPV16 antibody titers were examined. There were 43, 34, and 52 subjects with serum samples available for pretreatment, early, and late posttreatment intervals. Mean pretreatment antibody levels were higher than posttreatment antibody levels. Average antibody levels decreased significantly over time for E6 (Ptrend  0.001) and E7 (Ptrend <0.001). Six disease recurrences were observed during the follow-up period (median, 4.4 years). In univariate analysis, a log-unit increase in pretreatment E6 titer was significantly associated with increased risk of disease recurrence (HR, 5.42; 95% CI, 1.1â€"25.7; P  0.03). Therefore, levels of antibodies to HPV16 early oncoproteins decline after therapy. Higher E6 titers at diagnosis are associated with significant increases in the risk of recurrence. These data support the prospective evaluation of HPV16 antibodies as markers of surveillance and for risk stratification at diagnosis.

AB - Human papillomavirus (HPV) is responsible for increasing incidence of oropharyngeal cancer. At present, there are no biomarkers in the surveillance algorithm for HPV-positive oropharyngeal cancer (HPV-OPC). HPV16 E6 antibody precedes oropharyngeal cancer diagnosis. If HPV16 E6 indeed precedes primary diagnosis, it is similarly expected to precede disease recurrence and may have a potential role as a biomarker for surveillance of HPV-OPC. To determine whether HPV antibody titers have a potential role as early markers of disease recurrence or prognosis, a retrospective pilot study was designed to determine whether HPV16 early antibody titers E6, E7, E1, and E2 decrease after treatment of HPV16-positive OPC. Trends in pretreatment, early (6 months after treatment), and late posttreatment (>6 months after treatment) HPV16 antibody titers were examined. There were 43, 34, and 52 subjects with serum samples available for pretreatment, early, and late posttreatment intervals. Mean pretreatment antibody levels were higher than posttreatment antibody levels. Average antibody levels decreased significantly over time for E6 (Ptrend  0.001) and E7 (Ptrend <0.001). Six disease recurrences were observed during the follow-up period (median, 4.4 years). In univariate analysis, a log-unit increase in pretreatment E6 titer was significantly associated with increased risk of disease recurrence (HR, 5.42; 95% CI, 1.1â€"25.7; P  0.03). Therefore, levels of antibodies to HPV16 early oncoproteins decline after therapy. Higher E6 titers at diagnosis are associated with significant increases in the risk of recurrence. These data support the prospective evaluation of HPV16 antibodies as markers of surveillance and for risk stratification at diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84957961217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957961217&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0299

DO - 10.1158/1940-6207.CAPR-15-0299

M3 - Article

C2 - 26701665

AN - SCOPUS:84957961217

VL - 9

SP - 135

EP - 141

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -